Translate Bio to Participate in Upcoming Investor Conferences
September 03, 2020 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Second Quarter 2020 Financial Results and Reviews Recent Progress
August 06, 2020 16:14 ET
|
Translate Bio, Inc.
-- Expanded collaboration with partner Sanofi Pasteur for all infectious diseases further unites Translate Bio’s leading mRNA technology and large-scale manufacturing with Sanofi’s world class vaccine...
Translate Bio Announces Closing of Expanded Collaboration and Licensing Agreement with Sanofi Pasteur to Develop mRNA Vaccines for All Infectious Diseases
July 20, 2020 16:05 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Proposed Public Offering of Common Stock
June 24, 2020 16:18 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio to Present at Jefferies Virtual Healthcare Conference
May 28, 2020 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at the Bank of America Securities Virtual 2020 Healthcare Conference
May 12, 2020 16:05 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
May 07, 2020 16:26 ET
|
Translate Bio, Inc.
-- Pursuing development of mRNA vaccine against COVID-19 through expanded collaboration with Sanofi Pasteur -- -- Existing large-scale manufacturing capacity expected to help meet needs of...
Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19
March 27, 2020 02:00 ET
|
Translate Bio, Inc.
The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development PARIS and LEXINGTON, Mass., March 27,...
Translate Bio Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Progress
March 12, 2020 16:45 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis
February 26, 2020 07:30 ET
|
Translate Bio, Inc.
-- First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 -- LEXINGTON,...